Drug company CEOs admit prescription prices are too high. But will they change?
Together, the pharmaceutical companies that testified before Congress this week earn billions of dollars treating the world’s maladies and operating under the premise that today’s profits will fund research and development for tomorrow’s cures. But at what price?…
Watch 5:56
Lawmakers grill pharmaceutical executives over drug prices, but CEOs avoid big pledges
Health care costs are a major concern for Americans, who spend more on prescription drugs than residents of any other country. On Tuesday, executives from seven of the biggest pharmaceutical companies appeared before a Senate committee to explain their rising…
Pharma executives say they support ban on some anti-competitive practices
Some drugmakers have blocked competition for their medications by preventing would-be competitors from obtaining samples of the drugs. Drug executives who testified before Congress Tuesday said they do not use this tactic.
WATCH: Drug companies ‘bear none of the consequences’ of skyrocketing prices, Sen. Wyden says
The hearing marks the first time lawmakers have called top industry executives to account for rising prices that are squeezing Americans.
A new rule bans pharmaceutical companies from providing rebates to middlemen and insurers in exchange for choosing their drugs. Health and Human Services Secretary Alex Azar also called on Congress to pass a new prescription drug discount plan that would…
A day after unveiling the plan as a proposed regulation, Health and Human Services Secretary Alex Azar raised the stakes by calling on Congress to make it law and broaden it to include people covered by employer health insurance, not…
In our news wrap Thursday, President Trump denied knowing that former campaign chair Paul Manafort allegedly shared polling data with a Russian associate in 2016. The associate is accused of having ties to Russian intelligence. Also, rebels in Yemen attacked…
The package of bills are designed to link the prices Americans pay for prescription drugs to lower costs in other countries.
The proposal could create winners and losers among seniors, insurers, middlemen and drugmakers.
